Examining the Impact of Ertugliflozin on Cardiovascular Outcomes in Patients with Diabetes and Metabolic Syndrome: A Systematic Review of Clinical Trials

• Asıl Yazarlar: Silvius Alexandru Pescariu (Yazar), Ahmed Elagez (Yazar), Balaji Nallapati (Yazar), Felix Bratosin (Yazar), Adina Bucur (Yazar), Alina Negru (Yazar), Laura Gaita (Yazar), Ioana Mihaela Citu (Yazar), Zoran Laurentiu Popa (Yazar), Paula Irina Barata (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: MDPI AG, 2024-07-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Cardiovascular diseases (CVDs) constitute a significant cause of morbidity and mortality globally, particularly among individuals with type 2 diabetes mellitus (T2DM). Ertugliflozin, a Sodium-Glucose Co-transporter-2 (SGLT2) inhibitor, is hypothesized to confer cardiovascular protection; however, lo...